Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Dr. Geoffrey S. Ginsburg joins VisEn Medical's scientific advisory board

Abstract:
Heritage in Genomic Profiling and Molecular Medicine Tightly Linked with VisEn's Molecular Imaging Technology Platforms and Development Programs

VisEn Medical, Inc., a leader in fluorescence in vivo imaging of biologic and molecular activities from research through medicine, today announced that Geoffrey S. Ginsburg, M.D., Ph.D. has joined its Scientific Advisory Board.

Dr. Geoffrey S. Ginsburg joins VisEn Medical's scientific advisory board

Woburn, MA | Posted on December 8th, 2006

Dr. Ginsburg is Professor of Medicine and Pathology and Director of the Center for Genomic Medicine at Duke University's Institute for Genome Sciences & Policy. Dr. Ginsburg's work centers on the identification and application of predictive biomarkers in developing and applying novel therapies and for improved research and clinical medicine.

VisEn's fluorescence imaging technologies provide the industry's most robust imaging performance in identifying, characterizing and quantifying a range of biomarkers in vivo, including known molecular activities underlying disease states such as cancer, inflammation, cardiovascular and bone disease. By imaging these disease-related biological activities in vivo, VisEn's technology platforms enable expanded areas of research, more efficient drug development, and truly tailored clinical medicine into the future.

Kirtland G. Poss, President and Chief Executive Officer of VisEn commented on the announcement, "Dr. Ginsburg's deep heritage and expertise in genomics, biomarkers, pharmaceutical development and personalized medicine builds directly into VisEn's mission of developing and applying fluorescence imaging technologies from in vivo research through clinical medicine. We are honored by his participation with VisEn and see this as yet another key foundation for our company's leadership in clinically directed molecular imaging."

Dr. Ginsburg stated, "The future of clinical medicine will be built around linked understandings, readouts and treatments of disease-related biomarkers in patient populations. VisEn's real-time in vivo imaging of biologic and molecular processes is playing an increasingly central role in basic research and drug development today, and there is a close parallel between these approaches and the advanced molecular profiling work being carried out at our center."

"By bringing together the industry experts and leaders in the fields of genomics, biomarkers, imaging and therapeutic intervention, we will work to produce new approaches to pharmaceutical development and personalized medicine that will have a truly positive impact on healthcare delivery," added Dr. Ginsburg. "I look forward to collaborating even more deeply with VisEn's
leading Scientific Advisory Board to further advance this promising new area of medicine."

Prior to his academic career, Dr. Ginsburg was Director of Cardiovascular Disease and Vice President of Molecular and Personalized Medicine at Millennium Pharmaceuticals. In these roles, he was responsible for Millennium's personalized medicine initiatives to develop biomarkers for disease
and pharmacogenomic strategies for therapeutics and their implementation in the drug development process. His responsibilities also included translational research efforts and strategic academic alliances required to integrate genomics into the practice of medicine.

####

About VisEn Medical, Inc.
VisEn Medical, Inc. was founded in 2000 based on fluorescence imaging technologies initially developed at the Massachusetts General Hospital and
Harvard Medical School. VisEn is developing today's highest performing
fluorescence molecular imaging technology platforms, from research through
medicine. VisEn also works directly with its partners to design ranges of
tailored probes and applications that are targeted to their specific research
areas. Privately-held VisEn is headquartered in Woburn, Massachusetts and
has been financed by leading venture firms including Flagship Ventures and
The Bollard Group. For further information please visit http://www.visenmedical.com.

For more information, please click here

Contacts:
Bryan Murphy
LaVoie Group
978.745.4200 x105

Copyright © VisEn Medical, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Announcements

Virginia Tech physicists propose path to faster, more flexible robots: Virginia Tech physicists revealed a microscopic phenomenon that could greatly improve the performance of soft devices, such as agile flexible robots or microscopic capsules for drug delivery May 17th, 2024

Diamond glitter: A play of colors with artificial DNA crystals May 17th, 2024

Finding quantum order in chaos May 17th, 2024

Oscillating paramagnetic Meissner effect and Berezinskii-Kosterlitz-Thouless transition in cuprate superconductor May 17th, 2024

Tools

First direct imaging of small noble gas clusters at room temperature: Novel opportunities in quantum technology and condensed matter physics opened by noble gas atoms confined between graphene layers January 12th, 2024

New laser setup probes metamaterial structures with ultrafast pulses: The technique could speed up the development of acoustic lenses, impact-resistant films, and other futuristic materials November 17th, 2023

Ferroelectrically modulate the Fermi level of graphene oxide to enhance SERS response November 3rd, 2023

The USTC realizes In situ electron paramagnetic resonance spectroscopy using single nanodiamond sensors November 3rd, 2023

Appointments/Promotions/New hires/Resignations/Deaths

The National Space Society Mourns the Passing of Robert Krone, Founder of the Kepler Space Institute: Krone's Visionary and Humanistic Approach to the Study of Space Communities and Settlement Was Unique September 22nd, 2021

Leibniz Prize winner Professor Dr. Oliver G. Schmidt moves to Chemnitz University of Technology: President Professor Dr. Gerd Strohmeier refers to an 'absolute top transfer' September 10th, 2021

JEOL USA Welcomes New Managing Director, Hidetaka Sawada April 19th, 2021

The National Space Society Remembers Ben Bova : NSS Mourns the Loss of a Visionary NSS Leader December 2nd, 2020

Human Interest/Art

Drawing data in nanometer scale September 30th, 2022

Scientists prepare for the world’s smallest race: Nanocar Race II March 18th, 2022

Graphene nanotubes revolutionize touch screen use for prosthetic hands August 3rd, 2021

JEOL Announces 2020 Microscopy Image Grand Prize Winners January 7th, 2021

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project